Johannes Sumer
Division of Infectious Diseases, Infection Prevention and Travel Medicine · Dept. I
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Urwyler P, Leimbacher M, Charitos P, Moser S, Fehrman-Ekholm I, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci M, Huber L, Stüssi-Helbling M, Albrich W, Sendi P, Osthoff M. Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Front Immunol 2023; 14:1255292.
Oct 27, 2023Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Oct 27, 2023Front Immunol 2023; 14:1255292
Urwyler Pascal, Leimbacher Marina, Charitos Panteleimon, Moser Stephan, Fehrman-Ekholm Ingela, Trendelenburg Marten, Thoma Reto, Sumer Johannes, Camacho-Ortiz Adrián, Bacci Marcelo R, Huber Lars Chistian, Stüssi-Helbling Melina, Albrich Werner, Sendi Parham, Osthoff Michael
Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial.
Sumer J, Keckeis K, Scanferla G, Frischknecht M, Notter J, Steffen A, Kohler P, Schmid P, Roth B, Wissel K, Vernazza P, Klein P, Schoop R, Albrich W. Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial. Front Med (Lausanne) 2023; 10:948787.
Apr 17, 2023Novel Echinacea formulations for the treatment of acute respiratory tract infections in adults-A randomized blinded controlled trial.
Apr 17, 2023Front Med (Lausanne) 2023; 10:948787
Sumer Johannes, Keckeis Karin, Scanferla Giulia, Frischknecht Manuel, Notter Julia, Steffen Ana, Kohler Philipp, Schmid Patrick, Roth Bianca, Wissel Kerstin, Vernazza Pietro L, Klein Peter, Schoop Roland, Albrich Werner
Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort
Sumer J, Schlegel M, Vernazza P, Seneghini M, Nigg S, Risch L, Mueller N, Kahlert C, Flury D, Kohler P. Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort. Int J Public Health 2022; 67:1604147.
Feb 16, 2022Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic-A Prospective Cohort
Feb 16, 2022Int J Public Health 2022; 67:1604147
Sumer Johannes, Schlegel Matthias, Vernazza Pietro, Seneghini Marco, Nigg Susanne, Risch Lorenz, Mueller Nicolas J, Kahlert Christian, Flury Domenica, Kohler Philipp
Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study
Leal-Neto O, Kahlert C, Vernazza P, Kuster S, Babouee Flury B, Albrich W, Sumer J, Flury D, Schlegel M, Egger T, Kohler P. Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study. JMIR Public Health Surveill 2021; 7:e33576.
Nov 22, 2021Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study
Nov 22, 2021JMIR Public Health Surveill 2021; 7:e33576
Leal-Neto Onicio, Kahlert Christian, Vernazza Pietro, Kuster Stefan, Babouee Flury Baharak, Albrich Werner, Sumer Johannes, Flury Domenica, Schlegel Matthias, Egger Thomas, Kohler Philipp
Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study
Kahlert C, Albrich W, Babouee Flury B, Besold U, Fehr J, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Wiggli B, Vuichard-Gysin D, Stocker R, Persi R, Güsewell S, Egger T, Leal-Neto O, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clin Microbiol Infect 2021; 27:1336-1344.
May 19, 2021Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study
May 19, 2021Clin Microbiol Infect 2021; 27:1336-1344
Kahlert Christian, Albrich Werner, Babouee Flury Baharak, Besold Ulrike, Fehr Jan, Kuster Stefan, McGeer Allison, Risch Lorenz, Schlegel Matthias, Friedl Andree, Vernazza Pietro, Wiggli Benedikt, Vuichard-Gysin Danielle, Stocker Reto, Persi Raphael, Güsewell Sabine, Egger Thomas, Leal-Neto Onicio B, Sumer Johannes, Flury Domenica, Brucher Angela, Lemmenmeier Eva, Möller J Carsten, Rieder Philip, Kohler Philipp
An unusual case of multiple hepatic and pulmonary abscesses caused by Aggregatibacter aphrophilus in a young man: a case report
Sumer J, Haller S, Sawatzki M, Kellner J, Boggian K. An unusual case of multiple hepatic and pulmonary abscesses caused by Aggregatibacter aphrophilus in a young man: a case report. J Med Case Rep 2021; 15:34.
Feb 4, 2021An unusual case of multiple hepatic and pulmonary abscesses caused by Aggregatibacter aphrophilus in a young man: a case report
Feb 4, 2021J Med Case Rep 2021; 15:34
Sumer Johannes, Haller Sabine, Sawatzki Mikael, Kellner Jan, Boggian Katia
HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report
Sumer J, Waldeck F, Fischer N, Appenzeller C, Koster M, Früh M, Albrich W. HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report. Pneumonia (Nathan) 2021; 13:1.
Jan 25, 2021HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case report
Jan 25, 2021Pneumonia (Nathan) 2021; 13:1
Sumer Johannes, Waldeck Frederike, Fischer Nadja, Appenzeller Christina, Koster Markus, Früh Martin, Albrich Werner
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Urwyler P, Sendi P, Albrich W, Stüssi-Helbling M, Huber L, Bacci M, Camacho-Ortiz A, Sumer J, Thoma R, Trendelenburg M, Heijnen I, Moser S, Charitos P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials 2021; 22:1.
Jan 4, 2021Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Jan 4, 2021Trials 2021; 22:1
Urwyler Pascal, Sendi Parham, Albrich Werner, Stüssi-Helbling Melina, Huber Lars C, Bacci Marcelo R, Camacho-Ortiz Adrián, Sumer Johannes, Thoma Reto, Trendelenburg Marten, Heijnen Ingmar A F M, Moser Stephan, Charitos Panteleimon, Osthoff Michael
Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
Kohler P, Schlegel M, Risch L, Kuster S, McGeer A, Babouee Flury B, Albrich W, Notter J, Leal-Neto O, Güsewell S, Flury D, Sumer J, Kahlert C, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. Infect Control Hosp Epidemiol 2020; 42:604-608.
Oct 8, 2020Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
Oct 8, 2020Infect Control Hosp Epidemiol 2020; 42:604-608
Kohler Philipp, Schlegel Matthias, Risch Lorenz, Kuster Stefan, McGeer Allison, Babouee Flury Baharak, Albrich Werner, Notter Julia, Leal-Neto Onicio B, Güsewell Sabine, Flury Domenica, Sumer Johannes, Kahlert Christian, Vernazza Pietro